MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term non-motor, quality of life and safety results from the GLORIA registry

    K.R. Chaudhuri, Z. Pirtosek, B. Pickut, W. Poewe, F. Valldeoriola, L. Defebvre, R. Jech, P. Odin, C. Winkler, J. Szasz, K. Onuk, A. Yegin, L. Bergmann, A. Antonini (London, United Kingdom)

    Objective: To evaluate the tolerability and effect of levodopa-carbidopa intestinal gel (LCIG, designated in the US as carbidopa-levodopa enteral suspension) on non-motor symptoms (NMS), quality…
  • 2016 International Congress

    The effect of levodopa-carbidopa intestinal gel on activities of daily living: Results from the observational MONOTREAT study in advanced Parkinson’s disease patients

    R. Krüger, P. Lingor, T. Doskas, J. Henselmans, E.H. Danielsen, O. de Fabregues, A. Stefani, S.C. Sensken, J.C. Parra Riaza, K. Onuk, A. Yegin (Tübingen, Germany)

    Objective: To assess the tolerability and effect of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) on activities of daily…
  • 2016 International Congress

    Long-term safety of levodopa-carbidopa intestinal gel from an ongoing, open-label, phase 3 continued access to treatment study in advanced Parkinson’s disease patients

    R.L. Rodriguez, C. Zadikoff, A.J. Espay, V.S.C. Fung, C. Hall, W.Z. Robieson, K. Chatamra, S. Eaton, M.F. Facheris, J. Benesh (Orlando, FL, USA)

    Objective: To assess the safety and tolerability of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) in advanced Parkinson's disease…
  • 2016 International Congress

    ADS-5102 (amantadine HCl) extended-release capsules reduced levodopa-induced dyskinesia in the phase 3 EASE LID study

    R. Pahwa, C.M. Tanner, R.A. Hauser, P. Nausieda, D.D. Truong, K. Hull, P. Agarwal, R. Johnson, A.E. Ruby, N.L. McClure, M.J. Stempien (Kansas City, KS, USA)

    Objective: To investigate the efficacy and safety of ADS-5102 (amantadine HCl) extended release capsules 340 mg daily at bedtime for the treatment of levodopa-induced dyskinesia…
  • 2016 International Congress

    Differential clinical outcomes in unifocal vs. multifocal premotor rTMS for Parkinson’s disease: A randomized trial

    M.C. Biagioni, A.Y. Son, S. Agarwal, G. Dacpano, M. Brys, P. Kumar, A. Cucca, J. Singleton-Garvin, R. Gilbert, A. Quartarone, A. DiRocco (New York, NY, USA)

    Objective: To compare changes in clinical outcomes after weekly low-frequency (LF) repetitive transcranial magnetic stimulation (rTMS) sessions over one vs. two pre-motor cortex (preMC) areas…
  • 2016 International Congress

    Expiratory muscle training for the impaired loudness of speech in Parkinson’s disease: An open-label study

    S. Tomita, T. Oeda, A. Umemura, M. Kohsaka, K. Park, K. Yamamoto, H. Sugiyama, H. Sawada (Kyoto, Japan)

    Objective: To investigate the efficacy of EMT for the impaired loudness of speech in patients with PD, we conducted an open-label pilot trial of EMT.…
  • 2016 International Congress

    Changes in handwriting following repetitive transcranial magnetic stimulation over pre-motor cortex in Parkinson’s disease

    A.Y. Son, M.C. Biagioni, E. Pirraglia, A. DiRocco (New York, NY, USA)

    Objective: To observe changes in handwriting following administration of repetitive transcranial magnetic stimulation (rTMS) over pre-motor cortex (pre-MC) in patients with PD. Background: Patients with…
  • 2016 International Congress

    Feasibility of implementing a long-term mobile device program in PD patients

    L.R. Bataille, L.D. Herron, M. Afek, I. Feldman, C. Admati, S. Chowdhury (New York, NY, USA)

    Objective: To evaluate the feasibility of Parkinson's patients utilizing the Fox Insight Wear smartphone application in an environment outside the clinic. Background: A reliable quantitative…
  • 2016 International Congress

    VANTAGE trial: Three year outcomes of a prospective, multi-center trial evaluating deep brain stimulation with a new multiple-source, constant-current rechargeable system in Parkinson’s disease

    L. Timmerman, R. Jain, L. Chen, T. Brucke, F. Seijo, E. Suarez San Martin, C. Haegelen, M. Verin, V. Visser-Vandewalle, M.T. Barbe, S. Gill, A. Whone, M. Porta, D. Servello, F. Alesch (Cologne, Germany)

    Objective: The VANTAGE study assesses motor improvement in moderate-to-severe Parkinson's disease (PD) following bilateral subthalamic nucleus (STN) deep brain stimulation (DBS) using a new, implantable,…
  • 2016 International Congress

    Contributions of sensorial feedback to gait in Parkinson’s disease

    F.A. Barbieri, L.T.B. Gobbi, P.C.R. Santos, R. Vitório, L. Simieli, D. Orcioli-Silva, M.B. Pestana, C.M. Fiorelli, Q. Almeida (Bauru, Brazil)

    Objective: To evaluate the integration of optic flow and proprioception when people with Parkinson's disease (PD), under and without dopaminergic medication effects, and matched-control group…
  • « Previous Page
  • 1
  • …
  • 1720
  • 1721
  • 1722
  • 1723
  • 1724
  • …
  • 1734
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley